EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 3.0

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis

Jinchul Kim, Jinhyun Cho, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Cancer Research and Treatment · 2023

DOI: 10.4143/crt.2022.1658 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Research and Treatment, 2023. Verfasst von Jinchul Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Inha University College of Medicine, Incheon, Korea. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematopoietic Stem Cell Transplantation, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Inha University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.Materials and Methods R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and chimeric antigen receptor (CAR) T-cell therapy was used as reference treatment.

Results

Twenty-six ASCT-eligible cohorts from 17 studies comprising 2,924 patients and 59 ASCT-ineligible cohorts from 53 studies comprising 3,617 patients were included in the pooled analysis. In the ASCT-eligible group, the pooled 1-year PFS rate was 0.40 (95% confidence interval [CI], 0.15 to 0.65) for the CAR T-cell group and 0.34 (95% CI, 0.30 to 0.37) for the group with chemotherapy followed by ASCT intention. The two treatments were not significantly different in meta-regression analysis. In the ASCT-ineligible group, the pooled 1-year PFS was 0.40 (95% CI, 0.35 to 0.46) for CAR T-cell, and the highest primary outcome was 0.47 (95% CI, 0.37 to 0.57) for the tafasitamab group. CAR T-cell therapy showed significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group showed no different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.

Conclusion

Although several regimens were crudely grouped for classification, CAR T-cell therapy did not outperform chemotherapy followed by ASCT in the second-line setting or several recently developed agents in the ASCT-ineligible setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseHumansImmunotherapy, AdoptiveCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Meta-analysisPFS outcomeRegimenRelapsed/refractory large B-cell lymphoma

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology-Oncology, Inha University College of Medicine, Incheon, Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.

Förderung

  • Inha University

Zitieren

APA

Kim, J., Cho, J., Yoon, S. E., Kim, W. S., & Kim, S. J. (2023). Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis. Cancer Research and Treatment. https://doi.org/10.4143/crt.2022.1658

Vancouver

Kim J, Cho J, Yoon SE, Kim WS, Kim SJ. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis. Cancer Research and Treatment. 2023. doi:10.4143/crt.2022.1658

BibTeX
@article{Kim2023,
  author = {Kim, Jinchul and Cho, Jinhyun and Yoon, Sang Eun and Kim, Won Seog and Kim, Seok Jin},
  title = {Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis},
  journal = {Cancer Research and Treatment},
  year = {2023},
  doi = {10.4143/crt.2022.1658}
}
Kostenlos starten →